Возможность применения флурбипрофена у пациентов с дорсалгией

1. Jin Z, Wang D, Zhang H et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. An Rheumat Dis 2020; 79 (8): 1014–22. doi: 10.1136/annrheumdis-2020-217050
2. Парфенов В.А., Яхно Н.Н., Давыдов О.С. и др. Хроническая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2019; 11 (Спецвып. №2): 7–16. DOI: 10.14412/2074-2711-2019-2S-7-16
[Parfenov V.A., Yakhno N.N., Davydov O.S. et al. Khronicheskaya nespetsificheskaya (skeletno-myshechnaya) poyasnichnaya bol'. Rekomendatsii Rossiyskogo obshchestva po izucheniyu boli (ROIB). Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (Spetsvyp. №2): 7–16. DOI: 10.14412/2074-2711-2019-2S-7-16 (in Russian).]
3. Canizares M, Rampersaud YR, Badley E. The course of back pain in the Canadian population: trajectories, predictors, and outcomes. Arthritis Care Res (Hoboken). 2019; 71 (12): 1660–70. DOI: 10.1002/acr.23811
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74. DOI: 10.1136/annrheumdis-2013-204428 
5. Mutubuki E, Luitjens Mariette A, Maas E et al. Predictive factors of high societal costs among chronic low back pain patients. Eur J Pain 2020; 24: 325–37. DOI: 10.1002/ejp.1488
6. Montgomery W, Sato M, Nagasaka Y, Vietri J. The economic and humanistic costs of chronic lower back pain in Japan. Clin Econom Outcom Res 2017; 9: 361–71.  DOI: 10.2147/CEOR.S134130
7. Гусев Е.И., Никифоров А.С., Камчатнов П.Р. Неврологические симптомы, синдромы и болезни. 2-е изд. М.: ГЭОТАР-Медиа, 2014. 
[Gusev E.I., Nikiforov A.S., Kamchatnov P.R. Neurological symptoms, syndromes and diseases. 2nd ed. Moscow: GEOTAR-Media, 2014 (in Russian).]
8. Chou R, Côté P, Randhawa K et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low- and middle-income communities. Eur Spine J 2018; 27 (Suppl. 6): 851–60. DOI: 10.1007/s00586-017-5433-8
9. Камчатнов П.Р., Чугунов А.В., Ханмурзаева С.Б. Новые возможности лечения пациента с поясничной болью.Журн. неврологии и психиатрии им. C.C. Корсакова. 2017; 117 (12): 162–7. DOI: 10.17116/jnevro2017117121162-167
[Kamchatnov P.R., Chugunov A.V., Khanmurzaeva S.B. Novye vozmozhnosti lecheniia patsienta s poiasnichnoi bol'iu. Zhurn. nevrologii i psikhiatrii im. C.C. Korsakova. 2017; 117 (12): 162–7. DOI: 10.17116/jnevro2017117121162-167 (in Russian).]
10. Dionne RA, Snyder J, Hargreaves KM. Analgesic efficacy of flurbiprofen in comparison with acetaminophen, acetaminophen plus codeine, and placebo after impacted third molar removal. J Oral Maxillofac Surg 1994; 52: 919–24. 
11. Fujii Y, Itakura M. Comparison of lidocaine, metoclopramide, and flurbiprofen axetil for reducing pain on injection of propofol in japanese adult surgical patients: a prospective, randomized, double-blind, parallel-group, placebo-controlled study. Clin Therapeut 2008; 30 (2): 280–6.
12. Li J, Ye H, Shen W et al. Retrospective analysis of risk factors of postoperative nausea and vomiting in patients undergoing ambulatory strabismus surgery via general anaesthesia. Indian J Anaesth 2020; 64 (5): 375–82. DOI: 10.4103/ija.IJA_16_20
13. Wan Z, Chu C, Zhou R, Que B. Effects of oxycodone combined with flurbiprofen axetil on postoperative analgesia and immune function in patients undergoing radical resection of colorectal cancer. Clin Pharmacol Drug Dev 2020. doi: 10.1002/cpdd.818
14. Guven Z, Ofluoglu D, Ozaras N, Kayhan O. Kronik bel agrisinda flurbiprofenin etkinligi: placebo kontrollu cift kor calisma. Romatizma 2000; 15 (2): 161–5.
15. Khan D, Qindeel M, Ahmed N et al. Development of novel pH-sensitive nanoparticle-based transdermal patch for management of rheumatoid arthritis. Nanomedicine (Lond). 2020; 15 (6): 603–24. DOI: 10.2217/nnm-2019-0385
16. Hussain M, Shad I, Malik I et al. Hydroxypropylcellulose-flurbiprofen conjugates: design, characterization, anti-inflammatory activity and enhanced bioavailability. Saudi Pharm J 2020; 28 (7): 869–75. DOI: 10.1016/j.jsps.2020.06.009
17. Işıklan N, Erol ÜH. Design and evaluation of temperature-responsive chitosan/hydroxypropyl cellulose blend nanospheres for sustainable flurbiprofen release. Int J Biol Macromol 2020; 159: 751–62. DOI: 10.1016/j.ijbiomac.2020.05.071
18. Li P, Li H, Shu X et al. Intra-articular delivery of flurbiprofen sustained release thermogel: improved therapeutic outcome of collagenase II-induced rat knee osteoarthritis. Drug Deliv 2020; 27 (1): 1034–43. DOI: 10.1080/10717544.2020.1787555
19. Wang K, Zheng L, Luo T. Preoperative flurbiprofen axetil administration for acute postoperative pain: a meta-analysis of randomized controlled trials. J Anesth 2011; 31 (6): 852–60. 
20. Siegmett W, Noyelle R. Night pain and morning stiffness in osteoartritis: a crossover study of diclofenac and flurbiprofen. J Int Med Res 1988; 16: 182–8.
21. Guven Z, Ofluoglu D, Ozaras N, Kayhan O. Kronik bel agrisinda flurbiprofenin etkinligi: placebo kontrollu cift kor calisma. Romatizma 2000; 15 (2): 161–5.
22. Atiquzzaman M, Kopec J, Karim M et al. The role of NSAIDs in the association between osteoarthritis and cardiovascular diseases: a population‐based cohort study. Ann Rheum Dis 2018; 77 
(Suppl. 2):144. DOI:10.1002/art.41027
23. Szeto C-C, Sugano K, Wang J-G et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 0: 1–13. DOI: 10.1136/gutjnl-2019-319300
24. Rovenský J, Miceková D. Six-month prospective study to monitor the treatment of rheumatic diseases with sustained-release flurbiprofen. Drugs Exp Clin Res 2000; 26 (1): 19–24.
25. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909. DOI: 10.1136/bmj.j1909
26. Arfè A, Scotti L, Varas-Lorenzo C et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. DOI: 10.1136/bmj.i4857
27. Jonhson A, Nguyen T, Day R. Do nonsteroidal anti-inflammatory drugs on affect blood pressure? 
A meta-analysis. Ann Intern Med 1994; 121 (4): 289–300.
28. Murray MD, Greene PK, Brater DC. Effects of flurbiprofen on renal function in patients with moderate renal insufficiency. Br J Clin Pharmac 1992; 33; 385–393.
29. Janssen M, Caron M, van Rietbergen B et al. Impairment of the chondrogenic phase of endochondral ossification in vivo by inhibition of cyclooxygenase-2. Eur Cell Mater 2017; 34: 202–16. DOI: 10.22203/eCM.v034a13
30. Pourakbari R, Khodadadi M, Aghebati-Maleki A et al. The potential of exosomes in the therapy of the cartilage and bone complications; emphasis on osteoarthritis. Life Sci 2019; 236: 116861. DOI: 10.1016/j.lfs.2019.116861
31. Salari P, Abdollahi M. Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflammat Allergy/Drug Targ 2009; 8: 165–75.
32. Cui X, Ding Q, Shan R-N et al. Enantioseparation of flurbiprofen enantiomers using chiral ionic liquids by liquid-liquid extraction. Chirality 2019; 31 (6): 457–67. DOI: 10.1002/chir.23071
33. Mascagni P, Sabbatini V, Biordi L et al. R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production. Eur Cytokine Net 2000; 11 (2): 185–92.
34. Pratt V, McLeod H, Rubinstein W et al. Bethesda (MD): National Center for Biotechnology Information (US). 2012.

________________________________________________

1. Jin Z, Wang D, Zhang H et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. An Rheumat Dis 2020; 79 (8): 1014–22. doi: 10.1136/annrheumdis-2020-217050
2. Parfenov V.A., Yakhno N.N., Davydov O.S. et al. Khronicheskaya nespetsificheskaya (skeletno-myshechnaya) poyasnichnaya bol'. Rekomendatsii Rossiyskogo obshchestva po izucheniyu boli (ROIB). Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (Spetsvyp. №2): 7–16. DOI: 10.14412/2074-2711-2019-2S-7-16 (in Russian).
3. Canizares M, Rampersaud YR, Badley E. The course of back pain in the Canadian population: trajectories, predictors, and outcomes. Arthritis Care Res (Hoboken). 2019; 71 (12): 1660–70. DOI: 10.1002/acr.23811
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74. DOI: 10.1136/annrheumdis-2013-204428 
5. Mutubuki E, Luitjens Mariette A, Maas E et al. Predictive factors of high societal costs among chronic low back pain patients. Eur J Pain 2020; 24: 325–37. DOI: 10.1002/ejp.1488
6. Montgomery W, Sato M, Nagasaka Y, Vietri J. The economic and humanistic costs of chronic lower back pain in Japan. Clin Econom Outcom Res 2017; 9: 361–71.  DOI: 10.2147/CEOR.S134130
7. Gusev E.I., Nikiforov A.S., Kamchatnov P.R. Neurological symptoms, syndromes and diseases. 2nd ed. Moscow: GEOTAR-Media, 2014 (in Russian).
8. Chou R, Côté P, Randhawa K et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low- and middle-income communities. Eur Spine J 2018; 27 (Suppl. 6): 851–60. DOI: 10.1007/s00586-017-5433-8
9. Kamchatnov P.R., Chugunov A.V., Khanmurzaeva S.B. Novye vozmozhnosti lecheniia patsienta s poiasnichnoi bol'iu. Zhurn. nevrologii i psikhiatrii im. C.C. Korsakova. 2017; 117 (12): 162–7. DOI: 10.17116/jnevro2017117121162-167 (in Russian).
10. Dionne RA, Snyder J, Hargreaves KM. Analgesic efficacy of flurbiprofen in comparison with acetaminophen, acetaminophen plus codeine, and placebo after impacted third molar removal. J Oral Maxillofac Surg 1994; 52: 919–24. 
11. Fujii Y, Itakura M. Comparison of lidocaine, metoclopramide, and flurbiprofen axetil for reducing pain on injection of propofol in japanese adult surgical patients: a prospective, randomized, double-blind, parallel-group, placebo-controlled study. Clin Therapeut 2008; 30 (2): 280–6.
12. Li J, Ye H, Shen W et al. Retrospective analysis of risk factors of postoperative nausea and vomiting in patients undergoing ambulatory strabismus surgery via general anaesthesia. Indian J Anaesth 2020; 64 (5): 375–82. DOI: 10.4103/ija.IJA_16_20
13. Wan Z, Chu C, Zhou R, Que B. Effects of oxycodone combined with flurbiprofen axetil on postoperative analgesia and immune function in patients undergoing radical resection of colorectal cancer. Clin Pharmacol Drug Dev 2020. doi: 10.1002/cpdd.818
14. Guven Z, Ofluoglu D, Ozaras N, Kayhan O. Kronik bel agrisinda flurbiprofenin etkinligi: placebo kontrollu cift kor calisma. Romatizma 2000; 15 (2): 161–5.
15. Khan D, Qindeel M, Ahmed N et al. Development of novel pH-sensitive nanoparticle-based transdermal patch for management of rheumatoid arthritis. Nanomedicine (Lond). 2020; 15 (6): 603–24. DOI: 10.2217/nnm-2019-0385
16. Hussain M, Shad I, Malik I et al. Hydroxypropylcellulose-flurbiprofen conjugates: design, characterization, anti-inflammatory activity and enhanced bioavailability. Saudi Pharm J 2020; 28 (7): 869–75. DOI: 10.1016/j.jsps.2020.06.009
17. Işıklan N, Erol ÜH. Design and evaluation of temperature-responsive chitosan/hydroxypropyl cellulose blend nanospheres for sustainable flurbiprofen release. Int J Biol Macromol 2020; 159: 751–62. DOI: 10.1016/j.ijbiomac.2020.05.071
18. Li P, Li H, Shu X et al. Intra-articular delivery of flurbiprofen sustained release thermogel: improved therapeutic outcome of collagenase II-induced rat knee osteoarthritis. Drug Deliv 2020; 27 (1): 1034–43. DOI: 10.1080/10717544.2020.1787555
19. Wang K, Zheng L, Luo T. Preoperative flurbiprofen axetil administration for acute postoperative pain: a meta-analysis of randomized controlled trials. J Anesth 2011; 31 (6): 852–60. 
20. Siegmett W, Noyelle R. Night pain and morning stiffness in osteoartritis: a crossover study of diclofenac and flurbiprofen. J Int Med Res 1988; 16: 182–8.
21. Guven Z, Ofluoglu D, Ozaras N, Kayhan O. Kronik bel agrisinda flurbiprofenin etkinligi: placebo kontrollu cift kor calisma. Romatizma 2000; 15 (2): 161–5.
22. Atiquzzaman M, Kopec J, Karim M et al. The role of NSAIDs in the association between osteoarthritis and cardiovascular diseases: a population‐based cohort study. Ann Rheum Dis 2018; 77 (Suppl. 2):144. DOI:10.1002/art.41027
23. Szeto C-C, Sugano K, Wang J-G et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 0: 1–13. DOI: 10.1136/gutjnl-2019-319300
24. Rovenský J, Miceková D. Six-month prospective study to monitor the treatment of rheumatic diseases with sustained-release flurbiprofen. Drugs Exp Clin Res 2000; 26 (1): 19–24.
25. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909. DOI: 10.1136/bmj.j1909
26. Arfè A, Scotti L, Varas-Lorenzo C et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. DOI: 10.1136/bmj.i4857
27. Jonhson A, Nguyen T, Day R. Do nonsteroidal anti-inflammatory drugs on affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121 (4): 289–300.
28. Murray MD, Greene PK, Brater DC. Effects of flurbiprofen on renal function in patients with moderate renal insufficiency. Br J Clin Pharmac 1992; 33; 385–393.
29. Janssen M, Caron M, van Rietbergen B et al. Impairment of the chondrogenic phase of endochondral ossification in vivo by inhibition of cyclooxygenase-2. Eur Cell Mater 2017; 34: 202–16. DOI: 10.22203/eCM.v034a13
30. Pourakbari R, Khodadadi M, Aghebati-Maleki A et al. The potential of exosomes in the therapy of the cartilage and bone complications; emphasis on osteoarthritis. Life Sci 2019; 236: 116861. DOI: 10.1016/j.lfs.2019.116861
31. Salari P, Abdollahi M. Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflammat Allergy/Drug Targ 2009; 8: 165–75.
32. Cui X, Ding Q, Shan R-N et al. Enantioseparation of flurbiprofen enantiomers using chiral ionic liquids by liquid-liquid extraction. Chirality 2019; 31 (6): 457–67. DOI: 10.1002/chir.23071
33. Mascagni P, Sabbatini V, Biordi L et al. R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production. Eur Cytokine Net 2000; 11 (2): 185–92.
34. Pratt V, McLeod H, Rubinstein W et al. Bethesda (MD): National Center for Biotechnology Information (US). 2012.

А.В. Чугунов1, П.Р. Камчатнов*1, С.Б. Ханмурзаева2, А.М. Шемшединова2

1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия; 
2 ФГАОУ ВО «Дагестанский государственный медицинский университет» Минздрава России, Махачкала, Россия
*pavkam7@gmail.com 

________________________________________________

Aleksandr V. Chugunov1, Pavel R. Kamchatnov*1, Saida B. Khanmurzayeva2, Aminat M. Shemshetdinova2

1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Dagestan State Medical University, Makhachkala, Russia
*pavkam7@gmail.com